SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alliance Pharmaceutical
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Lane Hall-Witt who wrote (322)12/9/1998 4:15:00 PM
From: Cacaito   of 548
 
Du Pont files NDA for Definity (Perflutren) ultrasound contrast agent.

It is strong competition in this field and ahead of ALLP.

Du Pont already completed Phase III studies.

I guess there will be room for a second product and it validates the
technology approach.

ALLP claims to have patent protection for this technology, but not only
Dupont is developing it, there are other players and Sonus was recently
on a patent fight with another company. It seems everybody has patents,
on perflurocarbonates. 3M medical division is also developing this type
of products including a lung one.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News